Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

Electron microscopy evidence that cytoplasmic localization of the p16(INK4A) "nuclear" cyclin-dependent kinase inhibitor (CKI) in tumor cells is specific and not an artifact. A study in non-small cell lung carcinomas.

Evangelou K, Bramis J, Peros I, Zacharatos P, Dasiou-Plakida D, Kalogeropoulos N, Asimacopoulos PJ, Kittas C, Marinos E, Gorgoulis VG.

Biotech Histochem. 2004 Feb;79(1):5-10.

PMID:
15223748
2.

Expression of the p16(INK4a) gene product, methylation of the p16(INK4a) promoter region and expression of the polycomb-group gene BMI-1 in squamous cell lung carcinoma and premalignant endobronchial lesions.

Breuer RH, Snijders PJ, Sutedja GT, Sewalt RG, Otte AP, Postmus PE, Meijer CJ, Raaphorst FM, Smit EF.

Lung Cancer. 2005 Jun;48(3):299-306.

PMID:
15892997
3.

Immunohistochemical localization of c-mos at the light and electron microscope level in non-small cell lung carcinomas.

Evangelou K, Balaskas C, Marinos E, Dosios T, Kittas C, Gorgoulis VG.

Biotech Histochem. 2002 Mar;77(2):85-91.

PMID:
12083389
4.

[Correlation of P27 expression and localization to phosphorylated AKT in non-small cell lung cancer].

Miao LJ, Wang J, Li SS, Wu YM, Wu YJ, Wang XC.

Ai Zheng. 2006 Oct;25(10):1216-20. Chinese.

PMID:
17059763
5.

Differential retinoblastoma and p16(INK4A) protein expression in neuroendocrine tumors of the lung.

Dosaka-Akita H, Cagle PT, Hiroumi H, Fujita M, Yamashita M, Sharma A, Kawakami Y, Benedict WF.

Cancer. 2000 Feb 1;88(3):550-6.

PMID:
10649246
7.
8.
9.

Phenotype-rescue of cyclin-dependent kinase inhibitor p16/INK4A defects in a spontaneous canine cell model of breast cancer.

DeInnocentes P, Agarwal P, Bird RC.

J Cell Biochem. 2009 Feb 15;106(3):491-505. doi: 10.1002/jcb.22034.

PMID:
19130492
10.

Cytoplasmic, but not nuclear, p16 expression may signal poor prognosis in high-grade astrocytomas.

Arifin MT, Hama S, Kajiwara Y, Sugiyama K, Saito T, Matsuura S, Yamasaki F, Arita K, Kurisu K.

J Neurooncol. 2006 May;77(3):273-7. Epub 2006 Apr 14.

PMID:
16614947
11.

Expression of p14ARF, p15INK4b, p16INK4a, and DCR2 increases during prostate cancer progression.

Zhang Z, Rosen DG, Yao JL, Huang J, Liu J.

Mod Pathol. 2006 Oct;19(10):1339-43. Epub 2006 Jun 23.

12.

Aberrant expression of ID2 protein and its correlation with EBV-LMP1 and P16(INK4A) in classical Hodgkin lymphoma in China.

Zhao P, Lu Y, Liu L, Zhong M.

BMC Cancer. 2008 Dec 19;8:379. doi: 10.1186/1471-2407-8-379.

13.

Human p16gamma, a novel transcriptional variant of p16(INK4A), coexpresses with p16(INK4A) in cancer cells and inhibits cell-cycle progression.

Lin YC, Diccianni MB, Kim Y, Lin HH, Lee CH, Lin RJ, Joo SH, Li J, Chuang TJ, Yang AS, Kuo HH, Tsai MD, Yu AL.

Oncogene. 2007 Oct 25;26(49):7017-27. Epub 2007 May 7.

PMID:
17486064
14.
15.

Prognostic significance of p16(INK4a) hypermethylation in non-small cell lung cancer is evident by quantitative DNA methylation analysis.

Ota N, Kawakami K, Okuda T, Takehara A, Hiranuma C, Oyama K, Ota Y, Oda M, Watanabe G.

Anticancer Res. 2006 Sep-Oct;26(5B):3729-32.

16.

The p15(INK4b)/p16(INK4a)/RB1 pathway is frequently deregulated in human pituitary adenomas.

Ogino A, Yoshino A, Katayama Y, Watanabe T, Ota T, Komine C, Yokoyama T, Fukushima T.

J Neuropathol Exp Neurol. 2005 May;64(5):398-403.

17.

p16INK4A in oral squamous cell carcinomas--a correlation with biological behaviors: immunohistochemical and FISH analysis.

Suzuki H, Sugimura H, Hashimoto K.

J Oral Maxillofac Surg. 2006 Nov;64(11):1617-23.

PMID:
17052587
18.

Expression of senescence-related genes in human corneal endothelial cells.

Song Z, Wang Y, Xie L, Zang X, Yin H.

Mol Vis. 2008 Jan 29;14:161-70.

19.

Relationship between expression and methylation status of p16INK4a and the proliferative activity of different areas' tumour cells in human colorectal cancer.

Jie G, Zhixiang S, Lei S, Hesheng L, Xiaojun T.

Int J Clin Pract. 2007 Sep;61(9):1523-9. Epub 2007 May 30.

PMID:
17537196
20.

Tumor suppressor p16 INK4a: Downregulation of galectin-3, an endogenous competitor of the pro-anoikis effector galectin-1, in a pancreatic carcinoma model.

Sanchez-Ruderisch H, Fischer C, Detjen KM, Welzel M, Wimmel A, Manning JC, André S, Gabius HJ.

FEBS J. 2010 Sep;277(17):3552-63. doi: 10.1111/j.1742-4658.2010.07764.x. Epub 2010 Jul 31.

Items per page

Supplemental Content

Write to the Help Desk